Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Triastek Raises $20 Million for 3D Printing Manufacturing of Pharmaceuticals

publication date: Sep 28, 2023

Nanjing Triastek closed a $20 million Pre-C financing round to support development of its 3D printing process for complex drug delivery and programmed release medications. The company’s proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development techniques, have been put to use to create timed release drugs. Triastek is also developing new technology including Semi-Solid Extrusion, Micro-Injection Molding, and Micro-Droplet Jetting to deliver and develop oral peptides, gastric retention and high potency products. The round was led by Guoxin Investment. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital